Article
Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation.
Current allergy and asthma reports - 17 Feb 2026
Valent Peter, Hartmann Karin, Stefanzl Gabriele, Filik Yüksel, Bauer Karin, Degenfeld-Schonburg Lina, Gleixner Karoline V, Siebenhaar Frank, Niedoszytko Marek, Sperr Wolfgang R, Aghaallaei Narges, Hoermann Gregor, Sabato Vito, Orfao Alberto, Arock Michel, Akin Cem
Abstract excerpt
BACKGROUND: Systemic mastocytosis (SM) is a protean hematologic disorder characterized by uncontrolled expansion and accumulation of tissue mast cells (MC) in various organs, including skin, bone marrow, spleen, and gastrointestinal tract. In most cases, neoplastic cells exhibit the transforming KIT mutation D816V. Clinical symptoms arise from organ infiltration by neoplastic MC and/or pro-inflammatory mediators...
Topics
Join the communities discussing this publication.